Leerink Partnrs Has Negative Estimate for GPCR Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 EPS estimate for Structure Therapeutics, decreasing it from ($0.28) to ($0.38) per share, indicating a more negative outlook for the company's earnings.
• Structure Therapeutics recently reported a loss of ($0.36) per share, which was below analysts' consensus estimates, suggesting challenges in meeting financial expectations.
• Despite the negative forecast and recent earnings miss, eight analysts give Structure Therapeutics a "Buy" rating with an average price target of $75.71, reflecting potential confidence in the stock's long-term growth.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous forecast of ($0.28). The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics' FY2025 earnings at $1.50 EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at $0.75 EPS.

A number of other analysts have also weighed in on GPCR. JMP Securities dropped their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Guggenheim dropped their price target on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. Citigroup started coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target for the company. Finally, HC Wainwright lowered their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $75.71.

Structure Therapeutics Trading Down 2.3%

Shares of NASDAQ:GPCR traded down $0.44 during trading on Monday, reaching $18.73. 161,190 shares of the company traded hands, compared to its average volume of 876,008. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -17.78 and a beta of -1.89. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $45.37. The business's fifty day moving average is $19.58 and its 200-day moving average is $21.65.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GPCR. LPL Financial LLC grew its stake in shares of Structure Therapeutics by 6.0% during the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after acquiring an additional 646 shares during the period. Geode Capital Management LLC boosted its stake in Structure Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock worth $1,240,000 after purchasing an additional 480 shares during the period. Wells Fargo & Company MN raised its holdings in Structure Therapeutics by 202.5% during the 4th quarter. Wells Fargo & Company MN now owns 10,103 shares of the company's stock valued at $274,000 after buying an additional 6,763 shares during the period. Envestnet Asset Management Inc. raised its holdings in Structure Therapeutics by 12.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after buying an additional 843 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Structure Therapeutics by 9.1% during the 4th quarter. Russell Investments Group Ltd. now owns 34,671 shares of the company's stock valued at $940,000 after buying an additional 2,888 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.